FLOW vs TRIUMPH — genuinely asking which matters more
Trying to settle this properly because the thread from last year went in circles. The claim: FLOW matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 8 months without either producing anything. What would actually settle it is 3 people measuring the same thing…
off-label use data is different from approved-indication data
Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.
That is net peptide content, not purity. Different number, different meaning.
number-needed-to-treat is the house dialect